Every Form 4 that Grace Therapeutics, Inc. (GRCE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GRCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRCE filings page.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., identified as a 10% owner, reported two purchases by Opaleye, L.P.: 21,390 shares at a weighted average of $1.9258 per share on October 22, 2026, and 66,411 shares at a weighted average of $1.7679 per share on October 26, 2026. The weighted averages reflect multiple transactions within respective ranges of $1.91–$1.93 and $1.705–$1.79. No Rule 10b5-1 plan is reported. Opaleye Management disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. had a reported purchase of 4,256 common shares by Opaleye, L.P. on October 19, 2026, at $1.88 per share. Opaleye Management Inc., a 10 percent owner, reported the transaction as investment manager of the Fund; the position held directly by Opaleye, L.P. after the purchase was 2,948,610 shares. Opaleye Management may be deemed to beneficially own the Fund's shares, but disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 plan is reported.
Opaleye Management Inc., a 10% owner, reported three purchases of Grace Therapeutics, Inc. (GRCE) common stock held directly by Opaleye, L.P., the fund it manages. Opaleye, L.P. bought 11,233 shares on October 14, 2026, at a weighted-average price of $1.9349 per share; 23,485 shares on October 15 at $1.9453; and 36,347 shares on October 16 at $1.8917. The reported prices are weighted averages across multiple transactions.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye, L.P. purchased 7,215 shares on October 12, 2026, at $2.0200 per share; 5,340 shares on October 9 at a weighted average price of $2.0446 per share; and 2,077 shares on October 8 at $2.0175 per share. Opaleye Management Inc., a ten percent owner, reported the transactions. The shares are owned directly by Opaleye, L.P., and no Rule 10b5-1 plan is reported.
Opaleye Management, Inc., a ten percent owner of Grace Therapeutics, Inc. (GRCE) and investment manager of Opaleye, L.P., reported three purchases by the fund, which directly owns the shares, totaling 60,490 common shares. Opaleye, L.P. purchased 38,796 shares on October 1, 2026, at a weighted-average price of $2.0353 per share, with transaction prices ranging from $2.00 to $2.04; 20,000 shares on October 2, 2026, at a weighted-average price of $2.0684 per share, with transaction prices ranging from $2.03 to $2.07; and 1,694 shares on October 5, 2026, at $2.0600 per share. No Rule 10b5-1 plan is reported. Opaleye Management may be deemed to beneficially own the fund's shares but disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. (GRCE) reports that Opaleye, L.P. purchased 7,849 common shares on September 29, 2026, at $2.09 per share. The Fund’s reported position after the purchase was 2,798,167 shares. Opaleye Management Inc., identified as a 10% owner and the Fund’s investment manager, may be deemed to beneficially own the Fund’s shares but disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 plan is reported.
Grace Therapeutics, Inc. (GRCE) shares were purchased by Opaleye, L.P. in two reported transactions: 9,771 shares on September 21, 2026, and 5,318 shares on September 23, 2026, each at $2.10 per share. No Rule 10b5-1 plan is reported.
The amendment corrects the amount of securities beneficially owned after the transactions. The shares are owned directly by Opaleye, L.P.; Opaleye Management, Inc., its investment manager, may be deemed to beneficially own them and disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye, L.P. purchased 9,771 shares of common stock on September 21, 2026, and 5,318 shares on September 23, 2026, at $2.10 per share in each transaction. Opaleye Management, Inc., a ten percent owner and the Fund’s investment manager, may be deemed to beneficially own the Fund’s shares but disclaimed beneficial ownership except to the extent of its pecuniary interest therein.
Grace Therapeutics, Inc. (GRCE) director Edward Neugeboren received a grant of stock options for 12,200 shares of common stock on September 17, 2026. The options have an exercise price of $2.13 per share and expire on September 16, 2036. Half of the award vests immediately, with the remaining half vesting in substantially equal monthly installments over 12 months, subject to continuous service. No Rule 10b5-1 trading plan is reported for this grant.
Grace Therapeutics, Inc. (GRCE) reported that director Brian A. Davis received a grant of stock options covering 12,200 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.13 per share and expire on September 16, 2036.
According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over 12 months, subject to his continuous service. After this grant, he holds 12,200 options directly. No Rule 10b5-1 trading plan is reported.
Grace Therapeutics, Inc. (GRCE) reported that director Kavuru Vimal received a grant of stock options for 12,200 shares of common stock on September 17, 2026. The options carry an exercise price of $2.13 per share and expire on September 16, 2036.
According to the grant terms, 50% of the options vest immediately on the grant date, with the remaining 50% vesting in substantially equal monthly installments over a 12-month period, subject to Mr. Vimal’s continuous service. Following this award, he holds 12,200 options directly.
Grace Therapeutics, Inc. (GRCE) reported that director Kottayil George received a stock option grant covering 12,200 shares of common stock on September 17, 2026 at an exercise price of $2.13 per share. The option expires on September 16, 2036.
According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over a 12‑month period, subject to his continuous service on each vesting date. No Rule 10b5‑1 trading plan is reported for this award.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P. The fund bought 9,393 shares on September 8, 2026 at a weighted average price of $2.0972 per share and 5,836 shares on September 9, 2026 at a weighted average price of $2.0899 per share in open-market or private transactions. The prices reflect ranges of $2.095–$2.10 and $2.085–$2.09, respectively, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest; no Rule 10b5-1 trading plan is reported.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli purchased 100,000 shares of common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share. Following this purchase, he directly holds 121,357 shares of Grace Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Grace Therapeutics, Inc. (GRCE) reported that officer Kumar Amresh, VP Program Management, received a grant of stock options for 35,760 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27, with post-grant holdings of 35,760 options.
According to the award terms, the options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting over the following 11 quarters, subject to Mr. Amresh’s continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27. They vest quarterly over three years, with 1/12 vesting immediately and the remaining 11/12 in equal quarterly installments, subject to continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28. The options have an exercise price of $2.12 per share, expire on 2036-08-27, and relate to 267,160 shares of common stock. According to the vesting terms, 1/12 of the options vested immediately on the grant date and the remaining 11/12 vest in substantially equal quarterly installments over the following 11 quarters, subject to his continuous service.
Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27.
These options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting equally over the following 11 quarters, subject to his continuous service. Following this award, he holds 33,660 derivative securities of this type directly.
Grace Therapeutics, Inc. (GRCE) had a Form 4 filed for Opaleye Management Inc., a more-than-ten-percent holder, reporting an open-market purchase of 11,608 shares of common stock on August 14, 2026 at a weighted average price of $2.0853 per share. The shares are held indirectly by Opaleye, L.P., with Opaleye Management Inc. potentially deemed a beneficial owner through its role as investment manager but disclaiming beneficial ownership except to the extent of its pecuniary interest. Following this transaction, 2,760,000 shares are reported as held indirectly by Opaleye, L.P.
Grace Therapeutics, Inc. director Vimal Kavuru reported a grant of stock options on January 8, 2026. He received a stock option to buy 10,000 shares of Grace Therapeutics common stock at an exercise price of $3.8 per share, held in direct ownership. Following this grant, he beneficially owns options for 10,000 shares.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, provided he continues to serve the company through each vesting date.
Grace Therapeutics, Inc. director Kottayil George reported a grant of a stock option covering 10,000 shares of common stock of Grace Therapeutics. The option, with an exercise price of $3.8 per share, was awarded on January 8, 2026 and is held directly.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to George’s continued service on each vesting date.
Grace Therapeutics director Edward Neugeboren received a grant of stock options on January 8, 2026. The award is a stock option (right to buy) covering 10,000 shares of common stock at an exercise price of $3.8 per share, with no cost to receive the option itself.
According to the disclosure, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, as long as Neugeboren continues in service. After this grant, he holds 10,000 derivative securities directly.
Grace Therapeutics director reports stock option grant. Director Brian A. Davis reported receiving a stock option to buy 10,000 shares of Grace Therapeutics, Inc. common stock on January 8, 2026 at an exercise price of $3.8 per share. The filing shows that 25% of the option vests on the grant date, with the remaining 75% vesting in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to his continuous service. Following this grant, he beneficially owned 10,000 derivative securities directly.